You are provided with data from a dose-response experiment c…
You are provided with data from a dose-response experiment conducted on BaF3 pre-B lymphocytes engineered to express either wild-type or mutant forms of Bcr-Abl. The cells were tested in the presence or absence of IL-3. Based on the data, what conclusions can you draw regarding: (a) The efficacy of Gleevec? (b) The impact of the T315I mutation on Bcr-Abl function and drug resistance?